Chinese Sinovac Testing COVID-19 Vaccine in Brazil
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
Address: Unit 4106 Raffles City Office
Tower 268 Central Tibet Road,China
Tel: 86-21-6170-5300
One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
With many established products and services helping patients in nearly 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.
kidney disease, orthopaedics, oncology, transplant and immune disease, and diagnostic testing
In the race to develop the world’s first COVID-19 vaccine, Brazil – now one of the world’s worst-affected countries – is becoming an attractive clinical trial destination for biopharma companies…
The latest news from Chinese pharma, including the latest on Sinopharm’s COVID-19 vaccine, how geopolitical tensions are affecting trade between China and India, and the country’s latest pharma billionaire. …
I recently had the pleasure to moderate an event on the COVID-19 impact on the relationship between Doctor and Patient, attended by 50 executives of the French Healthcare community in…
Chinese biotech CanSinoBIO is racing against the clock to have a COVID-19 vaccine ready to begin production in early 2021. The firm’s senior VP of International Business Pierre Morgon reflects…
Founded by a veteran industry team, Arctic Vision recently celebrated its first anniversary and touts itself as the first innovative ophthalmology-focused biotech in China, with the mission of bringing innovative…
Dr Eddy Wu, founder and CEO of new Chinese ophthalmology biotech Arctic Vision outlines the specific unmet ophthalmology needs in the Chinese market, the company’s burgeoning international partnerships, exciting portfolio,…
Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology platform unique, and the challenges…
2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 – originating from the city…
A roundup of the latest news from Chinese biotechs, including a bumper IPO for Legend Biotech, a USD two million tie-up between Roche and Innovent Biologics, and a new Alphamab-Sanofi…
Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June 2019 and now stands as the largest such institution of 13 globally. JLABS @…
Pierre A Morgon, SVP International Business for CanSino Biotechnology (CanSinoBIO) – a Chinese vaccine biotech developing one of the frontrunner COVID-19 vaccine candidates – shares how his extensive international career…
Highly potent neutralizing antibodies may be the key to laying a foundation for COVID-19 treatment, according to a Chinese research team led by Peking University. The worldwide race against…
See our Cookie Privacy Policy Here
